SupremeToday Landscape Ad
Back
Next
Judicial Analysis Court Copy Headnote Facts Arguments Court observation
Listen Audio Icon Pause Audio Icon
judgment-img

2026 Supreme(Online)(Tel) 18267

IN THE HIGH COURT FOR THE STATE OF TELANGANA AT HYDERABAD
Nagesh Bheemapaka, J
Reddy’s Laboratories Limited – Appellant
Versus
Competition Commission of India – Respondent
WRIT PETITION No. 25689 OF 2024



Advocates:
For the Appellants/Petitioners: Avinash Desai, Kopal Sharraf
For the Respondents: N. Venkataraman, N. Bhujang Rao

High Courts should refrain from exercising writ jurisdiction under Article 226 to interfere with ongoing statutory inquiries at an intermediate stage. When a statute provides a comprehensive mechanism for adjudication and an appellate remedy, parties should exhaust those remedies rather than seek premature judicial intervention.

Headnote:(A) Competition Act, 2002 - Sections 3, 4, 15, 19, 26, 27 and 53A - Writ jurisdiction under Article 226 of the Constitution - Extraordinary jurisdiction not to be exercised against administrative/procedural orders at intermediate stages of inquiry - Principle of exhaustion of alternative remedies - Intervention at premature stage leads to fragmentation of proceedings - Delay in investigation does not automatically void proceedings in absence of specific prejudice or legislative consequence of nullification. (Paras 4, 5, 6, 7, 8, 15, 16, 17, 18, 31)

(B) Writ Petition - Maintainability - Challenge to procedural directions such as filing objections to investigation report or furnishing of financial statements is premature - No civil consequences or final adjudication at this stage - Courts must exercise restraint when statute provides for a complete adjudicatory and appellate mechanism. (Paras 5, 8, 14, 19, 21)

(C) Competition Law - Statutory Interpretation - Section 15 of the Act provides a curative mechanism protecting proceedings from being invalidated by reason of vacancy or defect in the composition of the regulatory body - Constitutional or statutory challenges regarding composition must be raised with promptitude and not reserved as tactical weapons. (Paras 24, 25)

Facts of the case:
A petition was filed challenging the directions issued by a regulatory body during an ongoing inquiry. The petitioner challenged the investigation report on grounds of delay, violation of procedures, and the lack of a judicial member in the regulatory body's composition. The petitioner also contested the demand for recent audited financial statements, arguing that any potential penalty should be linked to the period of the alleged contravention.

Findings of Court:
The court found that the impugned orders were merely procedural and directed towards ensuring a proper inquiry. It held that the statutory scheme provided sufficient safeguards and that the petitioner had an efficacious alternative remedy of appeal after the final order. The court also observed that the petitioner's delay-based contentions and constitutional challenges were either premature or lacked sufficient grounds for invocation of extraordinary writ jurisdiction.

Issues: Whether the High Court should entertain a writ petition against procedural orders passed during the investigation stage of a statutory inquiry, and whether alleged procedural irregularities in investigation warrant interference under Article 226.

Ratio Decidendi: High Courts should not exercise their extraordinary jurisdiction to interfere with ongoing statutory investigations that are at an intermediate stage, as the Act provides a complete mechanism for adjudication and appeal. Courts must respect the legislative intent of enabling authorities to function without fragmented interference, provided no fundamental rights are violated and no irreversible civil consequences have been imposed.

Result: Writ petition dismissed.

Table of Content
1. nature of petitioner's pharmaceutical business and procedural history of the competition commission investigation. (Para 1)
2. respondents' claims regarding the statutory authority to investigate and procedural necessity of financial disclosures. (Para 2)
3. interim procedural orders remain non-adjudicatory and outside writ jurisdiction. (Para 4 , 5 , 6 , 7 , 8)
4. distinction and inapplicability of precedents to premature judicial intervention. (Para 9 , 10)
5. merits of coercive conduct and prior exonerations are for the commission to decide. (Para 11 , 12 , 13 , 14 , 15)
6. procedural irregularities, delay, and composition defects do not invalidate ongoing statutory inquiries. (Para 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28)
7. dismissal of petition with liberty to raise merits before the commission. (Para 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36)

O R D E R:

Petitioner is a renowned pharmaceutical company engaged in the business of providing Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products across the world, and has earned global recognition for providing access to affordable and innovative medicines while investing in drug discovery, clinically differentiated assets and digital healthcare.

1.1. It is stated, petitioner Company, during various periods between the early 2000 and 2020, was a member of the Indian Drug Manufacturers' Association (IDMA), the country's largest pharmaceutical industry association for bulk drugs with over 1000 members, and is also a member of the Indian Pharmaceutical Alliance (IPA), an organization of research-based pharmaceutical companies in India, and like other pharmaceutical manufacturers, Petitioner Company was compelled to abide by the rules and regulations prescribed by such associations, including IDMA and IPA.

1.2. On 27.01.1997, a Memorandum of Understanding was executed between IDMA, Organization of Pharmaceutical Producers of India (OPPI) and All India Organization of Chemists and Druggists (AIOCD) governing practices relating to sale and distribution of pharmaceutical products including expiry norms, distribution norms, product information service system, supply of products through authorized stockists and issues relating to spurious drugs, and that the said Memorandum was entered into at a time when the Competition Act, 2002 (for short, ‘the Act’) was not in force in India, and that over the years and until the notification of Sections 3 and 4 of the Act on 20.05.2009, the parties had moved away from the practices prevalent in the 1997-era.

1.3. On 19.01.2012, Respondent No.6, namely Mr. Kailash Gupta, President of All India Chemists and Distributors Federation, filed information under Section 19(1)(a) of the Act alleging contravention of Sections 3 and 4 of the Act by AIOCD and various pharmaceutical manufacturers including Petitioner Company, and such allegations, as per the Petitioner, arise out of commercial rivalry between downstream trade associations, and that the Informant had primarily alleged breach of the Act by AIOCD.

1.4. It is contended, on 07.02.2012, the Commission passed an order under Section 26(1) of the Act forming only a prima facie opinion and directing investigation, wherein it relied upon the said Memorandum and observed that there existed a prima facie case of anti-competitive conduct, inter alia on the grounds that the Memorandum mandated obtaining of LOC/NOC from AIOCD prior to appointment of stockists, that AIOCD charged Rs.2000/- as Product Information Services and that the practices indicated existence of a cartel, though such findings were only at a preliminary stage and were yet to be established through cogent evidence relatable to the Act. Petitioner Company was wrongly impleaded as an opposite party by the said order dated 07.02.2012 despite being a mere manufacturing company and despite the Commission itself observing that manufacturers were v

Click Here to Read the rest of this document
1
2
3
4
5
6
7
8
9
10
11
SupremeToday Portrait Ad
supreme today icon
logo-black

An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers

Please visit our Training & Support
Center or Contact Us for assistance

qr

Scan Me!

India’s Legal research and Law Firm App, Download now!

For Daily Legal Updates, Join us on :

whatsapp-icon Back to top